Recent modifications accelerated portion of milestones remaining in firms' agreement over the next 12 months, reduced GSK's aggregate amount payable and forwarded $2m to NeuroMetrix. Firms are co-funding future development of Quell technology and additional TENS products for chronic pain beginning in 2019.
NeuroMetrix Inc. has received a $2m advance from GlaxoSmithKline PLC in a modification of the firms' agreement for GSK to provide up to $13.8m funding for development and commercialization of NeuroMetrix' Quell wearable pain-relief technology.
The modifications announced Dec. 11 accelerated a portion of milestones remaining in the firms' agreement over the next 12 months...
In remarks at recent investor conference reflecting comments from across the US consumer health sector, Kenvue chief Thibaut Mongon says, “I'm going to state the obvious. The environment is very fluid.”
The European OTC market grew at double the rate of the global market in the last twelve months, according to IQVIA Consumer Health, driven by a long-term trend for prevention. Consultancy Simon Kucher identifies a desire to live a longer, healthier life as the primary concern behind this trend.
Enterprise Investors takes 77% stake in Polish clean-label dietary supplements manufacturer Formeds.
Adopting an online approach, BioGaia is set to enter the Dutch market for probiotic dietary supplements. The firm announced the move as it reported lower sales in Q1.
Provisions in bill approved by Agriculture, Rural Development, FDA and Related Agencies Subcommittee aren’t likely to pass largely because they set a price too high for delta-8 THC and other ingredients to meet the definition of hemp as a de-scheduled substance.
Limited capacity and a two-to-three year timescale for reformulation could mean that many VMS supplements disappear from the market, warns EPPA partner Alexandra Bocquillion, speaking at the AESGP Annual Meeting in Warsaw, Poland.
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
